Related Experiment Video
Updated: May 23, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
19.7K
A noval identification of 4 systemic sclerosis - interstitial lung disease subgroups using principal component
Yaqi Zhao1, Baoting Chao2, Wei Xu1,3
1Department of Rheumatology and Immunology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
BMC Pulmonary Medicine
|May 21, 2025
Summary
Systemic sclerosis-interstitial lung disease (SSc-ILD) patient heterogeneity necessitates considering High-resolution computed tomography (HRCT) and antibody profiles for precise prognosis and treatment, not just histology.
Area of Science:
- Rheumatology
- Pulmonology
- Immunology
Background:
- Interstitial lung disease (ILD) is a severe complication of systemic sclerosis (SSc).
- Histologic classification of SSc-ILD may not fully capture clinical variations.
- Precise treatment requires early identification of SSc-ILD complications and patient subgroups.
Purpose of the Study:
- To examine clinical features of SSc-ILD.
- To aggregate SSc-ILD patients based on clinical manifestations, HRCT features, and antibody expression.
- To achieve precise treatment through early identification of complications.
Main Methods:
- Cluster analysis of 103 SSc-ILD patients.
- Utilized five clinical and serological variables.
- Compared survival rates and identified risk factors.
Main Results:
- Four distinct clusters were identified.
- Cluster 2 showed the worst prognosis and highest mortality.
- Albumin was a protective factor; age and IgM were risk factors.
Conclusions:
- Histologic typing alone is insufficient for SSc-ILD classification.
- HRCT features and antibody profiles are crucial for identifying homogeneous patient groups.
- Incorporating HRCT and antibody data can improve SSc-ILD prognosis and treatment.
